three years of sequence threads, summarised so you do not have to read them
three years of sequence threads, summarised so you do not have to read them. It is the sort of thing everyone half-believes and nobody writes down.
Every claim I could trace in this board went back to about four papers. That was a sobering afternoon.
Bought small, tested identity first, and only then thought about anything else. That order felt right.
Why identity, not purity, is the test to buy here.
This is a short peptide with a published sequence. Synthesis is not difficult, which means the market is wide and the analytical question shifts. A high area-percent figure tells you the sample is homogeneous; it does not tell you the homogeneous material is the sequence you ordered.
Mass spectrometry, with the theoretical mass alongside the measured one, converts a purity claim into an identity claim. It costs a little more and it answers the question that actually matters. Ask for it, and ask suppliers whether they can provide it before you order — the answers are informative in themselves.
Tell me where this is wrong. That is the useful part of posting it.
best — the order this archive was captured in
Left up. It distinguishes rodent work from human work, which is the standard on this board.
Left up.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.
preclinical enthusiasm is not clinical evidence
[removed by moderator]
the human evidence is thin and the rodent evidence is not
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
short peptides are cheap, which cuts both ways
Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.
Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.
a fifteen-residue peptide is easy to make and easy to make badly
pentadecapeptide, fifteen residues, and the sequence is public
Right, and regulatory status has genuinely moved in several jurisdictions.
baseline_drifter is right that a pure something-else is still something else.
regulatory status varies by jurisdiction and it has moved recently
regulatory status varies by jurisdiction and it has moved recently
This is the point that should be at the top of every thread here. Identity first.
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
- 1Right, and regulatory status has genuinely moved in several jurisdictions.…9 comments in this branch · started by u/baseline_drifter
- 2Left up. It distinguishes rodent work from human work, which is the standard…6 comments in this branch · started by u/bpc_sceptic